This abstract, presented in the 2016 World Congress of the World Federation of Hemophilia, reports a retrospective study evaluating the efficacy and FVIII concentrate consumption for daily tertiary prophylaxis in a group of severe hemophilia A adolescents (FVIII <1 % IU/dL) managed at the State University of Campinas referral center. The gene discussed is F8; the disease is hemophilia.